



Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.^{1,2}

1. AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.

2. AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

Management Team

Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

Michael S. Abrams

Chief Financial Officer

Recent News

Monday, October 18, 2021 - 07:50 AM

[Arch Therapeutics Launches Experts in Wound Care Program](#)

Wednesday, October 13, 2021 - 04:30 PM

[Arch Therapeutics Provides Corporate Update](#)

Wednesday, October 06, 2021 - 07:50 AM

[Arch Therapeutics to Present at the LD Micro Main Event](#)

Monday, October 04, 2021 - 07:50 AM

[Arch Therapeutics Launches Coverage and Reimbursement Pilot](#)

Thursday, September 30, 2021 - 07:50 AM

[Arch Therapeutics Announces Appointment of Larry Hicks to the Board](#)

Contact Information

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702

OTCQB: ARTH



Share Price	\$0.12
Volume	179.85k
Shares Outstanding	236,719,770
Market Cap	\$27.93m
52 Week High	\$0.20
52 Week Low	\$0.06

as of 10/22/2021

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.